JP2021528426A5 - - Google Patents

Info

Publication number
JP2021528426A5
JP2021528426A5 JP2020570975A JP2020570975A JP2021528426A5 JP 2021528426 A5 JP2021528426 A5 JP 2021528426A5 JP 2020570975 A JP2020570975 A JP 2020570975A JP 2020570975 A JP2020570975 A JP 2020570975A JP 2021528426 A5 JP2021528426 A5 JP 2021528426A5
Authority
JP
Japan
Prior art keywords
approximately
formula
optionally substituted
substituted
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020570975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021528426A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/037904 external-priority patent/WO2019246203A1/en
Publication of JP2021528426A publication Critical patent/JP2021528426A/ja
Publication of JP2021528426A5 publication Critical patent/JP2021528426A5/ja
Priority to JP2024119383A priority Critical patent/JP2024150688A/ja
Pending legal-status Critical Current

Links

JP2020570975A 2018-06-19 2019-06-19 mRNAおよび長い核酸の送達のための脂質ナノ粒子組成物 Pending JP2021528426A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024119383A JP2024150688A (ja) 2018-06-19 2024-07-25 mRNAおよび長い核酸の送達のための脂質ナノ粒子組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687010P 2018-06-19 2018-06-19
US62/687,010 2018-06-19
PCT/US2019/037904 WO2019246203A1 (en) 2018-06-19 2019-06-19 Lipid nanoparticle compositions for delivery of mrna and long nucleic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024119383A Division JP2024150688A (ja) 2018-06-19 2024-07-25 mRNAおよび長い核酸の送達のための脂質ナノ粒子組成物

Publications (2)

Publication Number Publication Date
JP2021528426A JP2021528426A (ja) 2021-10-21
JP2021528426A5 true JP2021528426A5 (cg-RX-API-DMAC7.html) 2022-06-27

Family

ID=68983272

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020570975A Pending JP2021528426A (ja) 2018-06-19 2019-06-19 mRNAおよび長い核酸の送達のための脂質ナノ粒子組成物
JP2024119383A Pending JP2024150688A (ja) 2018-06-19 2024-07-25 mRNAおよび長い核酸の送達のための脂質ナノ粒子組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024119383A Pending JP2024150688A (ja) 2018-06-19 2024-07-25 mRNAおよび長い核酸の送達のための脂質ナノ粒子組成物

Country Status (8)

Country Link
US (1) US20210121411A1 (cg-RX-API-DMAC7.html)
EP (1) EP3810148A4 (cg-RX-API-DMAC7.html)
JP (2) JP2021528426A (cg-RX-API-DMAC7.html)
CN (1) CN112543639A (cg-RX-API-DMAC7.html)
AU (2) AU2019288373B2 (cg-RX-API-DMAC7.html)
CA (1) CA3103528A1 (cg-RX-API-DMAC7.html)
GB (2) GB2596224B (cg-RX-API-DMAC7.html)
WO (1) WO2019246203A1 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102764250B1 (ko) 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
KR102712142B1 (ko) 2017-07-31 2024-10-07 리제너론 파마슈티칼스 인코포레이티드 Cas-형질전환 마우스 배아 줄기 세포 및 마우스 및 이것의 용도
CN111182790A (zh) 2017-07-31 2020-05-19 瑞泽恩制药公司 Crispr报告体非人类动物及其用途
WO2019067875A1 (en) 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
EP3592140A1 (en) 2018-03-19 2020-01-15 Regeneron Pharmaceuticals, Inc. Transcription modulation in animals using crispr/cas systems
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
GB2606038B (en) 2018-09-04 2023-05-03 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
GB2600800B (en) * 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス,インコーポレーテッド 第ix因子を発現するための組成物及び方法
WO2020247452A1 (en) 2019-06-04 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
CN113939595A (zh) 2019-06-07 2022-01-14 瑞泽恩制药公司 包括人源化白蛋白基因座的非人动物
KR20220024053A (ko) 2019-06-14 2022-03-03 리제너론 파마슈티칼스 인코포레이티드 타우병증의 모델
KR20220044816A (ko) * 2019-08-12 2022-04-11 인티그레이티드 나노테라퓨틱스 아이엔씨. 하전 물질 전달을 위한 지질, 이의 제형 및 그 제조 방법
US12521451B2 (en) 2019-11-08 2026-01-13 Regeneron Pharmaceuticals, Inc. CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
CN111467321A (zh) * 2020-03-26 2020-07-31 深圳市新合生物医疗科技有限公司 一种mRNA核酸类药物胞内递送系统、制备方法和应用
US20240293317A1 (en) * 2020-04-20 2024-09-05 Board Of Regents, The University Of Texas System Lipid nanoparticle (lnp) delivery systems and uses thereof
GB202008821D0 (en) * 2020-06-10 2020-07-22 Highersteaks Ltd Systems and methods for cell conversion
MX2023000511A (es) * 2020-07-10 2023-02-13 Genevant Sciences Gmbh Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines
MX2023011227A (es) 2021-03-22 2023-12-06 Recode Therapeutics Inc Composiciones y metodos para administracion dirigida a celulas.
MX2023011243A (es) 2021-03-23 2023-12-14 Recode Therapeutics Inc Composiciones de polinucleotidos, formulaciones relacionadas y metodos de uso de los mismos.
WO2022212838A1 (en) * 2021-04-02 2022-10-06 Tiba Biotech Llc Dendritic architectures as nonviral vectors in gene delivery
IL307526A (en) * 2021-04-13 2023-12-01 Westgene Biopharma Co Ltd Ionizable lipids and preparations for the transport of nucleic acids
CN113637708B (zh) * 2021-08-09 2023-07-25 中国科学院过程工程研究所 一种CRISPR-cas9基因编辑系统递送载体及其制备方法和应用
WO2023023055A1 (en) 2021-08-16 2023-02-23 Renagade Therapeutics Management Inc. Compositions and methods for optimizing tropism of delivery systems for rna
TW202328067A (zh) 2021-09-14 2023-07-16 美商雷納嘉德醫療管理公司 環狀脂質及其使用方法
WO2023044343A1 (en) 2021-09-14 2023-03-23 Renagade Therapeutics Management Inc. Acyclic lipids and methods of use thereof
US20250043269A1 (en) 2021-11-03 2025-02-06 The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad Precise Genome Editing Using Retrons
AU2022408167A1 (en) 2021-12-08 2024-06-06 Regeneron Pharmaceuticals, Inc. Mutant myocilin disease model and uses thereof
WO2023122752A1 (en) 2021-12-23 2023-06-29 Renagade Therapeutics Management Inc. Constrained lipids and methods of use thereof
US20260151350A1 (en) * 2021-12-27 2026-06-04 The Board Of Regents Of The University Of Texas System Compositions and methods for targeted delivery to cells
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
CA3255619A1 (en) 2022-04-07 2023-10-12 Renagade Therapeutics Management Inc. CYCLIC LIPIDS AND LIPID NANOPARTICLES (LPNs) FOR THE SUPPLY OF NUCLEIC ACIDS OR PEPTIDES INTENDED FOR USE IN VACCINATION AGAINST INFECTIOUS AGENTS
WO2023218420A1 (en) 2022-05-13 2023-11-16 Janssen Pharmaceuticals, Inc. Mrna compositions for inducing latent hiv-1 reversal
WO2024086929A1 (en) * 2022-10-25 2024-05-02 Nanovation Therapeutics Inc. Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
WO2024112775A1 (en) * 2022-11-25 2024-05-30 Beam Therapeutics Inc. Compositions and methods for editing a transthyretin gene
IL321026A (en) 2022-12-08 2025-07-01 Recode Therapeutics Inc Nanoparticle formulations and their uses
CN119343153A (zh) * 2022-12-27 2025-01-21 北京炫景瑞医药科技有限公司 一种治疗高尿酸相关疾病的核酸药物及其制备方法和用途
CN118946544A (zh) * 2023-03-09 2024-11-12 上海吉量医药工程有限公司 可离子化脂质分子及其制备方法和应用
EP4680595A2 (en) 2023-03-15 2026-01-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2024192291A1 (en) 2023-03-15 2024-09-19 Renagade Therapeutics Management Inc. Delivery of gene editing systems and methods of use thereof
CN116271105B (zh) * 2023-05-18 2023-08-25 上海贝斯昂科生物科技有限公司 一种适于rpe细胞转染的脂质纳米颗粒及其应用
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
US12599560B2 (en) 2023-11-02 2026-04-14 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025091377A1 (en) * 2023-11-02 2025-05-08 Longuide Biopharma Corporation Lipids and lipid nanoparticle formulations
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2025155753A2 (en) 2024-01-17 2025-07-24 Renagade Therapeutics Management Inc. Improved gene editing system, guides, and methods
WO2025166238A1 (en) 2024-01-31 2025-08-07 Orna Therapeutics, Inc. Fast-shedding polyethylene glycol lipids
WO2025174765A1 (en) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026122685A1 (en) 2024-12-03 2026-06-11 Orna Therapeutics, Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
WO2026165530A1 (en) 2025-02-03 2026-08-06 Renagade Therapeutics Management Inc. Hydrophilic polymer lipids for use in lipid nanoparticles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2289702C (en) * 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US7404969B2 (en) * 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
CA2760706C (en) * 2009-05-05 2019-08-06 Alnylam Pharmaceuticals, Inc. Methods of delivering oligonucleotides to immune cells
BR112014024131A2 (pt) * 2012-03-29 2017-07-25 Shire Human Genetic Therapies lipídios catiônicos ionizáveis
ES2967701T3 (es) * 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
KR102764250B1 (ko) * 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도

Similar Documents

Publication Publication Date Title
GB2589795A (en) Lipid nanoparticle compositions for delivery of MRNA and long nucleic acids
JP2022505234A5 (cg-RX-API-DMAC7.html)
US20260131020A1 (en) Ionizable cationic lipid for rna delivery
TWI887846B (zh) 用於抑制類血管生成素蛋白-3 (ANGPTL3)表現的RNAi藥劑及組合物及使用方法
JP2023549011A5 (cg-RX-API-DMAC7.html)
JP2018537403A5 (cg-RX-API-DMAC7.html)
JP4257697B2 (ja) シスプラチン内包高分子ミセルおよびその使用
US20170152223A1 (en) Lipid particles with cationic lipids for rna delivery
JP2025510229A5 (cg-RX-API-DMAC7.html)
JP2022501064A5 (cg-RX-API-DMAC7.html)
US20170101370A1 (en) Ionizable cationic lipid for rna delivery
CN101808651B (zh) 类固醇类的高分子结合物
CN119343373A (zh) 用于治疗强直性肌营养不良的肌肉靶向复合物的给药
JP2005513023A5 (cg-RX-API-DMAC7.html)
JP2024516164A5 (cg-RX-API-DMAC7.html)
JP2022543191A5 (cg-RX-API-DMAC7.html)
CN116924923A (zh) 阳离子脂质、脂质体及用途
JP7832717B2 (ja) 硫化物を含むイオン化可能な脂質、及びこれを含む脂質ナノ粒子
US20240294714A1 (en) Multi-motif dendrons and their supramolecular structures and uses thereof
JP2021524439A5 (cg-RX-API-DMAC7.html)
JP2022536993A5 (cg-RX-API-DMAC7.html)
JP2021534162A5 (cg-RX-API-DMAC7.html)
EP4602164A2 (en) Small interfering rna targeting c3 and uses thereof
CN117897152A (zh) 含有糖官能化核酸载体的纳米颗粒组合物
CN117915958A (zh) 作为在基因递送中的非病毒载体的树枝状结构